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Abstract Individuals with Down syndrome (DS) carry
three copies of the Cystathionine b-synthase (CbS) gene. The
increase in the dosage of this gene results in an altered profile
of metabolites involved in the folate pathway, including
reduced homocysteine (Hcy), methionine, S-adenosylho-
mocysteine (SAH) and S-adenosylmethionine (SAM). Fur-
thermore, previous studies in individuals with DS have
shown that genetic variants in genes involved in the folate
pathway influence the concentrations of this metabolism’s
products. The purpose of this study is to investigate whether
polymorphisms in genes involved in folate metabolism
affect the plasma concentrations of Hcy and methylmalonic
acid (MMA) along with the concentration of serum folate in
individuals with DS. Twelve genetic polymorphisms were
investigated in 90 individuals with DS (median age
1.29 years, range 0.07–30.35 years; 49 male and 41 female).
Genotyping for the polymorphisms was performed either by
polymerase chain reaction (PCR) based techniques or by
direct sequencing. Plasma concentrations of Hcy and MMA
were measured by liquid chromatography-tandem mass
spectrometry as previously described, and serum folate was
quantified using a competitive immunoassay. Our results
indicate that the MTHFR C677T, MTR A2756G, TC2 C776G
and BHMT G742A polymorphisms along with MMA con-
centration are predictors of Hcy concentration. They also
show that age and Hcy concentration are predictors of MMA
concentration. These findings could help to understand how
genetic variation impacts folate metabolism and what met-
abolic consequences these variants have in individuals with
trisomy 21.
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Introduction
Down syndrome (DS) is a chromosomal disorder caused by
the presence of three copies of chromosome 21 [1]. The
overexpression of genes involved in metabolic processes
results in biochemical aberrations. The effect on the vast,
integrated network of metabolic pathways leads to cellular
dysfunction and contributes to the unique pathogenesis of
DS [2].
Individuals with trisomy 21 present abnormalities in
folate metabolism that are attributed to the additional copy
of the Cystathionineb-synthase (CbS) gene located on
chromosome 21 [2, 3]. The CbS gene encodes an enzyme
that catalyzes the condensation of homocysteine (Hcy) and
serine to form cystathionine in the Hcy transsulfuration
pathway (Fig. 1). Thus, overexpression of the CbS gene
leads to an increase in the activity of this pathway. As a
result of the enhanced condensation of Hcy and
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cystathionine, there is a reduction in the concentration of
Hcy that is available for the remethylation reaction, which
is catalyzed by the vitamin B12-dependent enzyme methi-
onine synthase (MTR). Simultaneously, the hyperactivity
of the Hcy transsulfuration pathway leads to an accu-
mulation of 5-methyltetrahydrofolate (5-MTHF) and a
reduction in the conversion of 5-MTHF to tetrahydrofolate
(THF). THF is the metabolically active form of folate and
is required for de novo synthesis of nucleotides required for
RNA and DNA synthesis. Consequently, a functional folate
deficiency can be observed even in the presence of a nor-
mal or elevated concentration of folate [2]. In DS indi-
viduals, the extra copy of the CbS gene results in an altered
profile of metabolites involved in the methionine/Hcy
pathway, including reduced plasma concentrations of Hcy,
methionine, S-adenosylhomocysteine (SAH) and S-adeno-
sylmethionine (SAM) [2, 3].
Furthermore, studies have shown that genetic variants
involved in the folate metabolism can also affect the con-
centration of products derived from this metabolic process in
individuals with DS [4, 5]. Previously, we evaluated the
influence of the polymorphisms Methylenetrahydrofolate
reductase (MTHFR) C677T and A1298C, MTRA2756G, and
Reduced folate carrier 1 (RFC1) A80G on Hcy concentration
in 56 individuals with DS. We observed that the polymor-
phism A2756G of the MTR gene, which encodes a vitamin-
B12-dependent enzyme, influences Hcy concentrations in this
population [4]. In the present study, we extend this analysis to
90 individuals with DS. Here, we investigate the association
between twelve polymorphisms, MTHFR T1317C, Methio-
nine synthase reductase (MTRR) A66G, Transcobalamin 2
(TCN2) A67G and C776G, Betaine homocysteine methyl-
transferase (BHMT) G742A, Methylenetetrahydrofolate
dehydrogenase 1 (MTHFD1) G1958A, CbS T833C and
844ins68, MTHFR C677T, MTHFR A1298C, MTR A2756G
and RFC1A80G and the concentrations of serum folate,
plasma Hcy, and plasma methylmalonic acid (MMA), which
is an indicator of vitamin B12 status.
Materials and methods
This study’s protocol was approved by both the Research
Ethics Committee of Sa˜o Jose´ do Rio Preto Medical School
Fig. 1 Folate metabolism in Down syndrome individuals. Arrows
indicate direct and indirect alterations in metabolites induced by
cystathionine b-synthase (CbS) overexpression in DS individuals.
BHMT Betaine-homocysteine methyltransferase, CbS Cystathionine
b-synthase, CH3 Methyl, CH2THF Methylenetetrahydrofolate, CH3THF
Methyltetrahydrofolate, Cysta cystathionine, Cys cysteine; dATP
Deoxyadenosine 50-triphosphate, dGTP Deoxyguanosine 50-triphos-
phate, dTTP Deoxythymidine 50-triphosphate, Hcy Homocysteine,
L-MM-Coamutase L-methylmalonyl coenzyme A mutase, Met methi-
onine, MMA Methylmalonic acid, MTHFD1 Methylenetetrahydrofo-
late dehydrogenase 1, MTHFR Methylenetrahydrofolate reductase,
MTR Methionine synthase, MTRR Methionine synthase reductase,
RFC1 Reduced folate carrier 1, SAH S-adenosyl-homocysteine,
SAM S-adenosyl-methionine, TCN2 Transcobalamin 2, THF
Tetrahydrofolate
9278 Mol Biol Rep (2012) 39:9277–9284
123
(CEP-FAMERP, 165/2004) in Sa˜o Paulo State, and the
National Research Commission (CONEP) of Brazil. Ninety
DS individuals with full trisomy 21 (median age 1.29,
range 0.07–30.35 years-old; 49 male and 41 female) were
recruited at the General Genetics Outpatient Service of
Hospital de Base, Sao Jose do Rio Preto, SP, Brazil, after
family-informed consent forms were signed.
Fasting blood samples were collected for DNA extrac-
tion and separation of plasma and serum. Total plasma
concentrations of Hcy and MMA were measured by liquid
chromatography-tandem mass spectrometry [6–8]. Hcy
concentrations greater than 15 lmol/L were considered to
indicate hyperhomocysteinemia [9], and MMA concentra-
tions greater than 0.5 lmol/L defined vitamin B12 defi-
ciency (the conventional reference for vitamin B12
deficiency that was used was a concentration below
200 ng/L) [8, 10]. Folate concentrations were measured in
serum using a competitive immunoassay (Immulite kit,
DPC Medlab, Brazil), and concentrations less than
6.81 nmol/L were considered to indicate folate deficiency
in accordance with the manufacturer’s instructions.
Genomic DNA was extracted from peripheral blood
mononuclear cells using either a protocol described by
Miller et al. [11] or a GFX
TM
Genomic Blood DNA Puri-
fication Kit (GE Healthcare, USA). The genotypes of indi-
viduals at the polymorphisms MTHFRC677T, MTRA2756G,
RFC1A80G, CbS 844ins68, CbS T833C, and MTHFD
1G1958A were determined using previously described
methods [4, 12–15]. The variant C776G of the TCN2 gene
was analyzed by polymerase chain reaction-restriction
fragment length polymorphism (PCR-RFLP) using the
forward primer 50-CATCAGAACAGTGCGAGAGG-30
and the anti-sense primer described by Pietrzyk et al. [16].
The PCR products were digested with the Scrf1 enzyme.
The polymorphisms MTRRA66G, TCN2A67G and
BHMTG742A were genotyped by allelic discrimination
using Taqman probes (Applied Biosystems, Foster City,
CA, USA, TaqMan SNP genotyping assays
C__3068176_10; C__25967461_10 and C__11646606_20,
respectively). MTHFRA1298C and T1317C variants were
genotyped by direct sequencing as described elsewhere
[17] with the exception that the purification process used in
this study was performed using the enzymes exonuclease I
and shrimp alkaline phosphatase (Fermentas Life Sciences,
Brazil). This purification step was done in accordance with
the manufacturer’s instructions.
Statistical analyses
Concordance of genotype frequencies with Hardy–Wein-
berg equilibrium was evaluated by the Chi-squared test
using the BioEstat program (version 5.0), except for the
polymorphisms of RFC1 and CbS genes located on chro-
mosome 21. Because we used an RFLP-based method to
analyze variants in RFC1 and CbS, we were unable to
distinguish between heteroallelic individuals carrying one
or two copies of each allele.
Distributions of age and concentrations of plasma Hcy,
serum folate and plasma MMA were all skewed; therefore, a
logarithmic transformation was performed. To evaluate the
effect of the polymorphisms on each biochemical parameter,
linear regression analyses were performed. For Hcy analysis,
the genotypes for each polymorphism (dominant and
recessive models, separately), age, gender, folate concen-
tration, and MMA concentration were used as predictors. For
folate analysis, the predictors were the genotypes, age,
gender, Hcy concentration, and MMA concentration. For
MMA analysis, the genotypes, age, gender, folate concen-
tration and Hcy concentration were used as predictors.
Statistical analyses were performed using the Minitab
for Windows (Release 14) program. P values equal to or
less than 0.05 were considered significant.
Results
The genotype frequencies of the polymorphisms (Table 1) are
all in Hardy–Weinberg equilibrium. Hcy concentration was
quantified in 87 plasma samples (mean 5.78 ± 3.20 lmol/L;
median 4.75 lmol/L; range 1.26–20.90 lmol/L), and only
two individuals presented hyperhomocysteinemia. Of the 83
Table 1 Genotype frequencies of the polymorphisms in individuals
with Down syndrome
Wild-type
homozygous
n (%)
Heterozygous
n (%)
Mutant
homozygous
n (%)
MTHFR C677T 41 (45.6) 37 (41.1) 12 (13.3)
MTHFR A1298C 48 (53.3) 33 (36.7) 9 (10.0)
MTHFR T1317C 81 (90.0) 9 (10.0) 0
MTR A2756G 55 (61.1) 27 (30.0) 8 (8.9)
MTRR A66G 32 (35.6) 46 (51.1) 12 (13.3)
RFC1 A80Ga 15 (16.7) 62 (68.9) 13 (14.4)
TC2 A67G 72 (80.0) 15 (16.7) 3 (3.3)
TC2 C776G 37 (41.1) 45 (50.0) 8 (8.9)
CbS 844ins68a 69 (76.7) 21 (23.3) 0
CbS T883Ca 69 (76.7) 21 (23.3) 0
BHMT G742Ab 46 (51.7) 31 (34.8) 12 (13.5)
MTHFD1 G1958A 33 (36.7) 37 (41.1) 20 (22.2)
a The genotyping methods do not differentiate the presence of one or
two copies of each allele in heterozygous individuals (the gene is
located on chromosome 21 and is in triplicate in individuals with
Down syndrome)
b Genotyping one individual was not possible
Mol Biol Rep (2012) 39:9277–9284 9279
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individuals in which folate concentration was measured
(mean: 19.42 ± 11.48 ng/mL; median 15.80 ng/mL; range
4.70–72.0 ng/mL), none were deficient for this vitamin.
Based on MMA concentrations (mean 0.53 ± 0.80 lmol/L;
median 0.25 lmol/L; range: 0.09–4.77 lmol/L), we con-
cluded that 19 out of 85 individuals presented vitamin B12
deficiency.
Table 2 shows the mean values of Hcy, folate and MMA
that are associated with the genotypes in the dominant and
recessive models. Linear regression analyses considering
the dominant effect of the variant alleles showed that the
genotype MTR 2756 AG or GG is associated with increased
Hcy concentration (coefficient 0.267; P = 0.038). Con-
sidering the recessive effect of the variant alleles, the
genotypes MTHFR 677 TT (coefficient -0.420; P =
0.022), TC2 776 GG (coefficient -0.464; P = 0.050) and
BHMT 742 AA (coefficient -0.394; P = 0.036) were
associated with decreased Hcy concentration.
MMA concentration was inversely associated with age
in both dominant (coefficient -0.063; P = 0.001) and
recessive (coefficient -0.062; P \ 0.0001) models. Both
models also showed that MMA concentration and Hcy
concentration are mutually predictive; MMA concentration
is a predictor of Hcy concentration (Dominant model:
coefficient 0.184; P = 0.010; Recessive model: coefficient
0.158; P = 0.025) and vice versa (Dominant model:
coefficient 0.574; P = 0.010; Recessive model: coefficient
0.503; P = 0.025).
Discussion
Previous studies have shown that the presence of three
copies of the CbS gene and the resulting decrease in the
MTR-mediated reaction lead to disturbances in folate
metabolism in individuals with DS. The result is a func-
tional folate deficiency that may contribute to the meta-
bolic pathology of this complex genetic disorder [2].
Although the role of abnormal folate metabolism in the DS
phenotype is still unclear, Locke et al. [17] reported an
association between the polymorphisms RFC1 A80G and
MTHFR A1298C and the occurrence of atrioventricular
septal defect in individuals with DS. Moreover, it has been
hypothesized that abnormal folate metabolism due to CBS
overexpression could be related to the impaired DNA
repair capability observed in DS [18].
Hcy, vitamin B12, and folate are metabolic and nutri-
tional factors directly related to the folate pathway, and
alterations in their concentrations may indicate or lead to
disturbances in folate metabolism [2, 19]. Previous studies
have shown that genetic polymorphisms may influence
plasma concentrations of Hcy either directly or by affecting
plasma folate concentrations [5, 20–25]. Here, the results
Table 2 Mean values of Hcy, folate and MMA according to the
genotypes in the dominant and recessive models
Polymorphism Hcy
(lmol/L)
Folate
(ng/mL)
MMA
(lmol/L)
Dominant model
MTHFR C677T
CC 6.43 21.47 0.54
CT and TT 5.27 17.86 0.53
MTHFR A1298C
AA 5.48 19.23 0.59
AC and CC 6.20 19.90 0.48
MTHFR T1317Ca
TT 5.70 19.69 0.55
TC 6.97 18.31 0.45
MTR A2756Gb
AA 5.17 20.31 0.41
AG and GG 6.79 18.47 0.73
MTRR A66G
AA 5.87 21.04 0.64
AG and GG 5.67 19.78 0.35
RFC1 A80G
AA 6.57 23.29 0.50
AG and GG 5.37 19.79 0.19
TC2 A67G
AA 5.98 19.53 0.54
AG and GG 5.15 19.67 0.50
TC2 C776G
CC 5.85 17.53 0.47
CG and GG 5.24 21.54 0.55
MTHFD1 G1958A
GG 6.10 19.47 0.45
GA and AA 5.29 19.76 0.59
BHMT G742A
GG 6.60 20.10 0.65
AA and GA 4.96 19.21 0.43
CBS 844ins68a
SS 5.95 20.09 0.52
SM 5.37 17.61 0.58
CBS T833Ca
TT 5.95 20.09 0.52
TC 5.37 17.61 0.58
Recessive model
MTHFR C677Tb
CC and CT 6.08 20.16 0.58
TT 3.82 15.14 0.26
MTHFR A1298C
AA and AC 5.62 19.35 0.54
CC 7.54 21.21 0.51
MTR A2756G
AA and AG 5.84 19.60 0.49
GG 5.56 19.16 1.07
9280 Mol Biol Rep (2012) 39:9277–9284
123
indicate that the polymorphism MTHFR 677 TT is asso-
ciated with a decrease in Hcy concentration. This was an
unexpected finding as previous studies have shown that the
MTHFR 677 T allele is associated with reduced MTHFR
enzyme activity [26] and increased Hcy concentration [5,
20, 23–25]. Licastro et al. [5] observed elevated Hcy
concentrations in elderly DS individuals with the MTHFR
677 TT genotype; however, in other studies that used both
children and adults with DS, no association between the
MTHFR C677T polymorphism and Hcy concentration was
seen [19, 27]. Recently, Matteini et al. [28] observed an
association between the MTHFR 677 TT genotype and
decreased MMA concentration in patients with frailty
syndrome. Furthermore, they showed that improved B12
status was associated with this genotype. While this finding
is contrary to those of previous studies [23], it does cor-
roborate with our results. One explanation for the dis-
crepancies between the conclusions of these studies is that
the examined populations were different from one another
in age.
The results of the analysis of the association between
MTR 2756 genotypes and Hcy concentrations are consis-
tent with our previous observation of an association
between the G allele and increased Hcy concentrations in
DS individuals [4] and are also consistent with the results
of other studies of non-DS individuals [21, 22]. MTR is an
important vitamin B12-dependent enzyme involved in
folate metabolism. This enzyme catalyzes the transmeth-
ylation of Hcy to methionine in a reaction that utilizes
methyl-tetrahydrofolate (CH3THF) as a methyl group
donor (Fig. 1). There are still no studies evaluating the
difference between the enzymatic activity of the wild- and
variant-types of MTR, but the association of the variant
MTR 2756 G with increased Hcy concentration suggests
that this polymorphism could result in an impaired enzyme
[4, 21, 22].
To the best of our knowledge, this is the first study to
investigate the influence of polymorphisms in genes
encoding the BHMT and MTHFD1 proteins in individuals
with DS. The former is a protein that remethylates Hcy to
methionine using betaine as the methyl donor [29], and the
latter is a protein known to catalyze the conversion of THF
to the corresponding 10-formyl, 5,10-methenyl and 5,10-
methylene derivatives [30] (Fig. 1). In the present study, no
associations were found between Hcy, folate and MMA
concentrations and the polymorphism MTHFD1G1958A.
Our results, however, did show a connection between the
variant BHMT 742 AA genotype and decreased plasma
Hcy concentration. This polymorphism produces two dis-
tinct alloenzymes, which exhibit significant differences in
Km values for Hcy and betaine [31]. The Km values of the
variant alloenzyme are lower than those of the wild-type.
The decreased Km of the alloenzyme may be responsible
for the increased efficiency of Hcy remethylation, which
requires betaine as a methyl group donor, [32], reducing
Hcy concentration. Furthermore, studies have suggested a
protective role of the homozygous AA genotype against
neural tube defects [33] and cardiovascular disease [34],
suggesting that the BHMT 742 G allele may have a dele-
terious effect on Hcy metabolism. Supporting this
hypothesis and consistent with our findings, the BHMT 742
AA genotype was associated with lower Hcy concentra-
tions in a previous study [33].
The TCN2 enzyme encodes a transport protein required
for cellular uptake of B12. This vitamin functions as co-
factor of MTR, an important enzyme in folate metabolism
that catalyzes the transmethylation of Hcy to methionine in
a reaction that utilizes methyl-tetrahydrofolate (CH3THF)
as a methyl group donor (Fig. 1). In the present study, the
TCN2 776 GG genotype was associated with reduced Hcy
concentration. In agreement with our results, Brouns et al.
[35] reported an association between the TCN2 776 G
allele and a reduction in Hcy concentration observed in the
amniotic fluid of pregnancies with a child having a com-
plex birth defect an index for fetal metabolism. Previously
published data show that the TCN2 776 G allele is asso-
ciated with decreased transcription and decreased concen-
trations of cellular and plasma transcobalamin, the carrier
protein that delivers vitamin B12 to cells [36]. This suggests
Table 2 continued
Polymorphism Hcy
(lmol/L)
Folate
(ng/mL)
MMA
(lmol/L)
MTRR A66G
AA and AG 5.52 19.46 0.54
GG 7.87 20.20 0.48
RFC1 A80G
AA and AG 5.99 19.88 0.57
GG 4.74 17.63 0.32
TC2 A67G
AA and AG 5.84 19.49 0.54
GG 4.88 21.20 0.29
TC2 C776Gb
CC and CG 6.02 18.92 0.56
GG 3.57 26.47 0.22
MTHFD1 G1958A
GG and GA 5.89 19.69 0.53
AA 5.57 19.10 0.54
BHMT G742Ab
GG and GA 6.04 19.81 0.57
AA 4.53 18.04 0.32
a The homozygous mutant genotype was not present in the sample
b Polymorphism associated with modulation of Hcy in the linear
regression
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that the TCN2 776 G allele may encode a protein that is
less efficient in delivering B12 to tissues. The negative
impact of the TCN2 776 G allele on the intracellular
availability of vitamin B12 is demonstrated by this vari-
ant’s association with a lower mean concentration of the
transcobalamin-vitamin B12 complex (holotranscobalam-
in) [36–38] in addition to increased MMA [39] and Hcy
concentrations [37, 40]. Previous studies, however, did
not find an association between this polymorphism and
either holotranscolbalamin [41] or Hcy [38, 42]. Fur-
thermore, an increase in Hcy concentration was shown to
be associated with the heterozygous TCN2 776 CG
genotype when compared to the homozygous genotypes
[36]. The discrepancy between these studies may be the
result of several variables, such as differences in age,
ethnicity, gender of the study subjects, folate intake,
vitamin B12 and B6 intakes, genetic factors, and study
design [4, 43, 44].
In this study, MMA concentration was inversely asso-
ciated with age. Previous studies have shown that vitamin
B12 concentration is inversely correlated with age [45, 46],
corroborating with these findings, once MMA concentra-
tion reflects inversely the status of vitamin B12. Vitamin
B12 acts as a cofactor of the L-methylmalonyl-CoA mutase
enzyme (Fig. 1), and its deficiency avoids the conversion
of methylmalonyl-CoA to succinyl-CoA. This blockage
diverts the substrate for MMA synthesis and leads to an
increase in the concentrations of MMA and Hcy [47, 48].
Taken together, the results from previous studies that show
a negative correlation between the concentration of vitamin
B12 and Hcy [49] are in agreement with our observation of
a positive correlation between the concentrations of MMA
and Hcy.
Lastly, in July of 2004, the Brazilian government
mandated that grain products must be fortified with folic
acid [50]. The ensuing programs focused on increasing the
dietary intake of folate to approximately 150 mg per per-
son per day depending on the diet. This policy was
implemented in order to reduce the incidence of neural
tube defects. In the USA, fortification of grain products
with folic acid led to a decrease in the mean Hcy con-
centration from 10.1 to 9.4 mmol/L [51]. Moreover, it is
believed that the change in dietary intake of folate in the
Brazilian population will significantly affect these values in
the Brazilian population. We believe that such an obser-
vation would have an impact on the concentrations of
folate and Hcy in our DS sample.
In conclusion, our results indicate that the MTHFR
C677T, MTR A2756G, TC2 C776G and BHMT G742A
polymorphisms along with MMA concentration are pre-
dictors of Hcy concentration. They also show that age and
Hcy concentration are predictors of MMA concentration.
These findings could help to understand how genetic
variation impacts folate metabolism and what metabolic
consequences these variants have in individuals with tri-
somy 21.
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